Share

EORTC website certified by HONcode

This past March 2009 the EORTC website was certified by HONcode, a code of ethical conduct established by the Health On the Net (HON) Foundation. HON is a non-governmental organization internationally recognized for its pioneering work in the field of health information ethics. The HONcode is a set of principles established by HON and designed to hold Web site developers to basic ethical and quality standards in the presentation of information.

Accreditation of a website is based on a website’s compliance with the HONcode principles. The HONcode principles ensure that readers always know the source and the purpose of the data they are reading, and that their privacy and confidentiality are respected. Furthermore, it requires that website contact details be transparent, the funding sources of the site be clearly disclosed, and the advertising policy of the site be clearly stated.

The HONcode seal can be found on the EORTC homepage. This seal is directly linked to a HONcode accreditation certificate located on the HON website.

John Bean

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023